Bladder cancer is one of most common malignant cancers worldwide and has the highest recurrence rate of any solid tumor. Currently the major treatment of bladder cancer is surgery and chemotherapy. The therapeutic effect is still not satisfactory, Patients who underwent radical cystectomy had a 5-year overall survival rate of 66% and a 10-year survival rate of 43%, and there is still a lack of public recognized, universally applicable bladder cancer diagnosis and prognostic evaluation markers.
Biomarkers are tools used to more accurately identify high-risk individuals, to speed the diagnosis, and to help in treatment and prognosis determination. Biomarkers can be classified based on different parameters, including their characteristics, such as imaging biomarkers (echocardiography, computed tomography, magnetic resonance imaging) or molecular biomarkers.
The goal of this Special Issue is to summarize new advances in both molecular and imaging biomarkers of bladder cancer, especially in risk prediction, screening, diagnosis, and prognosis. Original research and review articles are both welcome in order to best understand the importance of different biomarkers in bladder cancer.
Potential topics include but are not limited to the following:
• Advances in molecular biomarkers and bladder cancer
• Advances in imaging biomarkers and bladder cancer
• The synergy of molecular and imaging biomarkers in predicting and detecting bladder cancer
• The synergy of molecular and imaging biomarkers in the assessment of prognosis in bladder cancer
• Biomarkers for the evaluation of drug resistance in bladder cancer
Bladder cancer is one of most common malignant cancers worldwide and has the highest recurrence rate of any solid tumor. Currently the major treatment of bladder cancer is surgery and chemotherapy. The therapeutic effect is still not satisfactory, Patients who underwent radical cystectomy had a 5-year overall survival rate of 66% and a 10-year survival rate of 43%, and there is still a lack of public recognized, universally applicable bladder cancer diagnosis and prognostic evaluation markers.
Biomarkers are tools used to more accurately identify high-risk individuals, to speed the diagnosis, and to help in treatment and prognosis determination. Biomarkers can be classified based on different parameters, including their characteristics, such as imaging biomarkers (echocardiography, computed tomography, magnetic resonance imaging) or molecular biomarkers.
The goal of this Special Issue is to summarize new advances in both molecular and imaging biomarkers of bladder cancer, especially in risk prediction, screening, diagnosis, and prognosis. Original research and review articles are both welcome in order to best understand the importance of different biomarkers in bladder cancer.
Potential topics include but are not limited to the following:
• Advances in molecular biomarkers and bladder cancer
• Advances in imaging biomarkers and bladder cancer
• The synergy of molecular and imaging biomarkers in predicting and detecting bladder cancer
• The synergy of molecular and imaging biomarkers in the assessment of prognosis in bladder cancer
• Biomarkers for the evaluation of drug resistance in bladder cancer